Valuation
- Market cap
- 124,123,000
- Revenue TTM
- $30,910,000
- Net income TTM
- $-74,280,000
- P/E (trailing)
- 29.29
- P/E (forward)
- —
- Profit margin
- -240.31%
- Debt to equity
- 0.00
Trading
- Volume
- 534,200
- Avg volume
- 915,282
- Day's range
- $1.94 – $2.08
- Shares out
- 59,963,000
- Stochastic %K
- 57%
- Beta
- 3.22
- Analysts
- Moderate Buy
- Price target
- $5.00
Company profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell...
Show more
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 586 3100
- Website
- https://foghorntx.com
- Address
- 99 Coolidge Avenue, Suite 500, Watertown, United States
Latest news
No headlines yet.